Trial Comparing Glucantime Alone vs. with CO2 Laser for Cutaneous Leishmaniasis
A randomized controlled trial is underway to assess the efficacy of intralesional Glucantime alone versus in combination with fractional CO₂ laser therapy for cutaneous leishmaniasis.
Phase III
Infectious Disease / Parasitic Infections
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
This trial could redefine treatment standards for cutaneous leishmaniasis by potentially integrating CO₂ laser therapy as a standard adjunctive treatment. Successful outcomes may enhance patient satisfaction and alter market dynamics for existing therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for healing outcomes and cosmetic improvements, as well as any reported adverse events.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.